Study aims to uncover hidden side effects of common adrenal cancer drug
NCT ID NCT00568139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 400 people with adrenocortical carcinoma who are taking mitotane as their first treatment. The goal is to carefully record all side effects, including ones that are not well understood. By collecting this data, researchers hope to improve how side effects are managed in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mitotane
- What this could lead to
- If successful, this study could provide clearer information on mitotane's side effects, helping doctors manage treatment better.
- What could go wrong
- This is an observational study, not testing a new treatment. It only documents known side effects, so it won't improve outcomes directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
Würzburg, 97080, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver tumors targeted directly: old pump, new drug
- New registry aims to unlock secrets of rare adrenal cancer
- Scientists search for keys to unlock immune attack on rare adrenal cancer
- Scientists investigate adrenal tumors and seek better therapies
- New hope for rare cancers? drug combo shows promise in early trial
- Immunotherapy drug tested against rare adrenal cancer